Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Benicar Gains New Approval | Contract Pharma

What are you searching for?

Sign in

Benicar Gains New Approval

Daiichi Sankyo, Inc. received approval from the FDA for its hypertension treatment Benicar (olmesartan medoxomil) for use in children and adolescents 6 to 16 years of age.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Daiichi Sankyo, Inc. received approval from the FDA for its hypertension treatment Benicar (olmesartan medoxomil) for use in children and adolescents 6 to 16 years of age.

“As hypertension is on the rise also in a younger population, Daiichi Sankyo believes it is important to help doctors meet the challenge of treating these pediatric patients by providing a treatment option to help people effectively manage their hypertension,” said Reinilde Heyrman, M.D., vice president clinical development, operations, Daiichi Sankyo Pharma Development.

The approval was based on a Phase III study examining the antihypertensive effects of Benicar in pediatric patients. The study found the drug to be safe and effective in children ages 6-16 with hypertension, resulting in statistically significant blood pressure reductions compared to placebo. Benicar was originally approved for the treatment of hypertension in adults in 2002.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters